Compare AIRE & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | ICCC |
|---|---|---|
| Founded | 2021 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 55.5M |
| IPO Year | N/A | 1987 |
| Metric | AIRE | ICCC |
|---|---|---|
| Price | $0.46 | $6.32 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 6.1M | 36.3K |
| Earning Date | 11-12-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $4,149,567.00 | ★ $27,769,304.00 |
| Revenue This Year | $456.19 | N/A |
| Revenue Next Year | $105.16 | N/A |
| P/E Ratio | ★ N/A | $23.43 |
| Revenue Growth | ★ 994.18 | 16.49 |
| 52 Week Low | $0.14 | $4.28 |
| 52 Week High | $2.29 | $7.60 |
| Indicator | AIRE | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 60.98 |
| Support Level | $0.40 | $5.80 |
| Resistance Level | $0.60 | $7.12 |
| Average True Range (ATR) | 0.04 | 0.34 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 27.74 | 50.64 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.